vTv Therapeutics (VTVT) Consolidated Net Income (2014 - 2026)

vTv Therapeutics (VTVT) has 13 years of Consolidated Net Income data on file, last reported at $24.1 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 488.19% year-over-year to $24.1 million; the trailing twelve-month figure through Mar 2026 stood at -$729000.0 (up 96.82% YoY), and the FY2025 full-year result was -$31.1 million, down 36.89% from the prior year.
• Consolidated Net Income climbed to $24.1 million in Q1 2026, from -$7.1 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $24.1 million in Q1 2026 to a low of -$10.3 million in Q3 2025.
• A 5-year average of -$4.7 million and a median of -$6.1 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income tumbled 386.44% in 2022 and jumped 488.19% in 2026, its largest moves.
• Tracing VTVT's Consolidated Net Income over 5 years: stood at -$6.1 million in 2022, then gained by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then tumbled by 60.87% to -$7.1 million in 2025, then soared by 438.11% to $24.1 million in 2026.
• Business Quant data shows VTVT's Consolidated Net Income at $24.1 million in Q1 2026, -$7.1 million in Q4 2025, and -$10.3 million in Q3 2025.